Roivant Sciences Ltd. ROIV 深 滬
等待開盤 05-20 09:30:00 美东时间
28.21
-0.340
-1.19%
華盛通- 最 高28.70
- 今 開28.47
- 成交量 413.18万股
- 最 低 27.85
- 昨 收 28.55
- 總市值 201.90亿
- 52周最高 30.33
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 10.705
- 委 比 -96.01%
- 總股本 7.16亿
- 歷史最高 30.33
- 量 比 0.53
- 振 幅 2.98%
- 歷史最低 2.52
- 每 手 1
- 風險率 6.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘后 | Pershing Square Inc.涨4.09%，Roblox Corp. Class A涨3.26%
Pershing Square Inc.涨4.09%；Roblox Corp. Class A涨3.26%；HF Sinclair Corporation涨3.04%
19分钟前
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks
Foreign healthcare stocks are earning some of the market's strongest Quant conviction right now, with the top five names on this ranking all carrying scores above 4.19, a cluster of high-conviction si...
05-07 19:50
UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales
UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to decline
05-01 18:38
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to declin
05-01 18:30
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
04-22 01:58
Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio
Roivant Sciences ( ($ROIV) ) has provided an update. On April 2, 2026, Roivant ...
04-02 19:41
Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris
Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris Priovant, backed by Roivant, began enrolling subjects in a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first patients enrolled in March 2026. Prior results have already been reported from an inv
04-02 17:00
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit Roivant filed an amended Form 8-K to correct its earlier report by filing the Settlement Agreement as an exhibit. The amendment relates to a March 3, 2026 settlement between Genevant and Arbutus and Moderna that resolves p
03-23 20:44
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
莫德纳解决LNP专利纠纷 将支付22.5亿美元和解金
莫德纳（Moderna，MRNA）同意向Roivant Sciences（ROIV）支付高达22.5亿美元，以解决与其COVID-19疫苗相关的脂质纳米颗粒...
03-04 21:35
